Fly News Breaks for February 13, 2020
Feb 13, 2020 | 07:32 EDT
Cowen analyst Chris Shibutani lowered his price target on Nektar to $30 from $40after updating his model to include the failure of oxycodegol and the new development plan for bempeg. The analyst removed the pain opportunity and added the new early line settings for bempeg in bladder and melanoma which have potentially larger opportunities but comes with less visibility. Shibutani maintained his Outperform rating on Nektar shares.
News For NKTR From the Last 2 Days
There are no results for your query NKTR